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HIV-1 tat expression and
sulphamethoxazole hydroxylamine
mediated oxidative stress alter the disulfide
proteome in Jurkat T cells
Kemi Adeyanju1,2, John R. Bend3, Michael J. Rieder4,5† and Gregory A. Dekaban1,2*†
Abstract
Background: Adverse drug reactions (ADRs) are a significant problem for HIV patients, with the risk of developing ADRs
increasing as the infection progresses to AIDS. However, the pathophysiology underlying ADRs remains unknown.
Sulphamethoxazole (SMX) via its active metabolite SMX-hydroxlyamine, when used prophylactically for pneumocystis
pneumonia in HIV-positive individuals, is responsible for a high incidence of ADRs. We previously demonstrated that the
HIV infection and, more specifically, that the HIV-1 Tat protein can exacerbate SMX-HA-mediated ADRs. In the current
study, Jurkat T cell lines expressing Tat and its deletion mutants were used to determine the effect of Tat on the
thiol proteome in the presence and absence of SMX-HA revealing drug-dependent changes in the disulfide
proteome in HIV infected cells.
Protein lysates from HIV infected Jurkat T cells and Jurkat T cells stably transfected with HIV Tat and Tat deletion
mutants were subjected to quantitative slot blot analysis, western blot analysis and redox 2 dimensional (2D) gel
electrophoresis to analyze the effects of SMX-HA on the thiol proteome.
Results: Redox 2D gel electrophoresis demonstrated that untreated, Tat-expressing cells contain a number of
proteins with oxidized thiols. The most prominent of these protein thiols was identified as peroxiredoxin. The
untreated, Tat-expressing cell lines had lower levels of peroxiredoxin compared to the parental Jurkat E6.1 T cell
line. Conversely, incubation with SMX-HA led to a 2- to 3-fold increase in thiol protein oxidation as well as a
significant reduction in the level of peroxiredoxin in all the cell lines, particularly in the Tat-expressing cell lines.
Conclusion: SMX-HA is an oxidant capable of inducing the oxidation of reactive protein cysteine thiols, the majority of
which formed intermolecular protein bonds. The HIV Tat-expressing cell lines showed greater levels of oxidative stress
than the Jurkat E6.1 cell line when treated with SMX-HA. Therefore, the combination of HIV Tat and SMX-HA appears to
alter the activity of cellular proteins required for redox homeostasis and thereby accentuate the cytopathic effects
associated with HIV infection of T cells that sets the stage for the initiation of an ADR.
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Background
Oxidative stress represents an imbalance in cellular
homeostasis due to either the excessive production of
reactive oxygen species (ROS), the impairment of cellu-
lar anti-oxidant defenses or both, which can lead to a
disruption of redox control and signaling that can result
in molecular damage [1]. During HIV infection, oxida-
tive stress contributes to the impaired responsiveness,
apoptosis and depletion of CD4+ T cells [2–6]. In
addition, there is a strong association between decreased
survival of HIV-infected individuals and low thiol levels
[2, 7, 8]. This oxidative stress is primarily due to the
HIV-1 transactivator of transcription (Tat) [9].
Tat influences the cellular redox state by two mecha-
nisms; by depleting antioxidant concentrations and/or
increasing oxidant levels. The capacity of Tat to decrease
antioxidant concentrations is linked to the suppression
of manganese superoxide dismutase (Mn-SOD) expres-
sion as well as its ability to directly decrease cellular
glutathione (GSH) content by down-regulating glutathi-
one synthetase [10–12]. In addition, Tat can induce ROS
production in multiple cell types [13–15].
Tat is encoded by two exons and synthesized at early
and late stages of HIV-1 replication [16]. However,
during the viral life cycle, two different forms of Tat are
generated. One is the product of two splicing events of
the HIV-1 transcript that produces a full-length protein
of 101 amino acids [17]. The second form encoded by
only the first exon is 72 amino acids in length. In vitro,
both variants efficiently transactivate HIV-1-specific
transcription [18, 19]. Tat also contains a protein trans-
duction domain (PTD) which enables the protein to be
secreted from HIV-1-infected cells and enter uninfected
cells to regulate host gene expression [16, 20]. The PTD
also serves as a nuclear localization sequence (NLS) that
restricts Tat to the nucleus preventing Tat from interact-
ing with cellular protein that can result in cytopathic
effects as we have recently demonstrated [21].
As HIV infection progresses to AIDS, there is a
dramatic increase in the incidence of hypersensitivity
adverse drug reactions (ADRs) [22]. These ADRs arise
from the treatments involving all antiretroviral drug
classes as well as medications used to treat opportunistic
infections that arise during HIV disease progression
[22]. The drug reported to produce the highest incidence
of HIV-associated ADRs is Sulphamethoxazole (SMX), a
sulphonamide used to prevent and treat pneumocystis
pneumonia, a common opportunistic infection in indi-
viduals with advanced AIDS [23].
The major route of metabolism for SMX is N-
acetylation in the liver, a detoxication reaction that results
in a product rapidly eliminated from the body [24, 25]. A
small and patient-variable fraction of a given dose of SMX
is also oxidized by the P450 monooxygenase isozyme
CYP2C9 to the reactive metabolite Sulphamethoxazole-
hydroxylamine (SMX-HA). Further auto-oxidation gives
rise to Sulphamethoxazole-nitroso (SMX-NO), an electro-
phile that can react covalently with cellular proteins form-
ing haptens [26]. SMX-HA, and subsequently SMX-NO,
can also be generated by dendritic cells and by myeloper-
oxidase (MPO) in activated neutrophils, monocyte/macro-
phages and lymphocytes [24, 25, 27, 28].
The mechanism(s) that lead(s) to the development of
SMX-mediated ADRs is incompletely understood, how-
ever. There is evidence that in the absence of adequate
detoxication, electrophilic SMX-NO preferentially react
with reactive cysteine thiols of cellular proteins to form
hapten-protein conjugates. Ionized protein cysteines are
stronger nucleophiles than unionized protein thiols and
serve as a very common site for covalent reaction with
drug electrophiles [29]. Such drug hapten-protein conju-
gates can form neo-antigens that are recognized by the
immune system [25, 30]. Upon processing and presenta-
tion of the hapten-protein conjugate, immune responses
can be directed against all or part of the SMX-protein
conjugate, which clinically manifests as a hypersensitivity
ADR. Thus, the oxidative stress inherent during an HIV
infection that results in reduced concentrations of the
protective antioxidant GSH [2, 31, 32] and the formation
of SMX-hapten-protein conjugates creates an environ-
ment favoring the development of ADRs in HIV+ patient
populations that are progressing to AIDS.
Low levels of ROS cause reversible post-translational
modifications of proteins and function as second messen-
gers in signal transduction pathways to regulate multiple
biological processes [33]. With increasing ROS concentra-
tion, the sulfur-containing residues, cysteine and methio-
nine, are susceptible to oxidation and undergo reversible
and non-reversible reduction–oxidation (redox) reactions
[34, 35]. The oxidation and reduction of these ionized
(reactive) cysteine residues primarily forms the basis of
redox signalling [33]. The oxidation of reactive cyst-
eine residues leads to formation of disulfide bonds
(Cys-S-S-Cys) and cysteine-sulfenic (Cys-SOH), −sulfinic
(Cys-SO2H) and -sulfonic (Cys-SO3H) acids [33, 34].
Reactive (ionized) cysteine thiol residues in proteins also
react with GSH (S-glutathionylation) to form protein-
glutathione mixed disulfides (PSSG) or to cysteine resi-
dues in other proteins to form protein-protein disulfides
(PSSP) when GSH is depleted [34–36]. Importantly, Tat
expression not only alters the overall pattern of gene ex-
pression within the infected cell, but also decreases intra-
cellular GSH [9, 10, 12] and therefore may alter the
disulfide proteome resulting in a cellular environment
more susceptible to oxidative damage, cell death and
ultimately to hypersensitivity ADRs.
The transactivation activity of Tat on HIV LTR-
initiated RNA transcription is redox sensitive. The HIV
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Tat protein contains 7 cysteines that each form one or
more disulfide bonds that are required for maximal Tat
transactivator function [37, 38]. Protein disulfide for-
mation is favored in a pro-oxidative environment.
Under normoxic conditions, Tat functions optimally
with respect to LTR-initiated transcription. However, in
anoxic conditions or upon exposure to strong reducing
agents Tat function is reduced or abolished, respectively
[37, 38]. Thus, depending on the anatomical location of
HIV infected T- and myeloid cells, Tat activity will, in
part, be dictated by the pO2 concentration. Hence, Tat
activity may be higher in the blood and intestine where
pO2 levels range at higher levels (5.3–13.2% pO2)) com-
pared to the lower levels reported for brain, skin and
secondary lymphoid organs (< 4.4% pO2;) [38, 39].
We have previously developed Tat green fluorescent pro-
tein (GFP) fusion protein mutants to map the Tat region
that contributes to the development of ADRs [21, 40]. The
mutants include the full-length protein (Tat101GFP) and
the product of the first exon (Tat72GFP), both of which
have the NLS that restricts them to the nucleus. Add-
itionally, a TatΔGFP mutant was created expressing the
full-length protein with a deleted NLS that resulted in
significant cytoplasmic distribution of the protein [21].
These constructs are expressed under the control of an
inducible promoter so that the expression of these Tat
mutant proteins approximated the level of expression
achieved in HIV infected T cells. These cell lines express
the recombinant proteins of the expected molecular
weight and exhibit the expected intracellular distribution
in the nucleus and cytoplasm depending on whether the
NLS has been retained in a given mutant. These mutant
forms of Tat enhance, to varying degrees, SMX-HA-
mediated toxicity as we have observed in wildtype HIV in-
fected T cells. These constructs, their induction character-
istics, impact on cell viability and the degree to which they
induce ROS have been reported in detail elsewhere [21,
40].
In the present study, we examined the changes in the
cellular redox state of wildtype and mutant forms of
Tat-expressing T cells in the absence and presence of
SMX-HA by evaluating the disulfide proteome using a
redox 2D SDS-PAGE system. We also determined the
impact of SMX-HA and Tat on the oxidation level of
peroxiredoxin 1, an endogenous redox sensitive protein.
This report represents the first analysis of the cellular
thiol proteome following HIV infection thereby defining
the extent to which the virus alters the redox state at the
molecular level under normoxic conditions.
Methods
Cell lines
The human T lymphocyte cell line Jurkat E6.1 (ATCC
TIB-152), was obtained from the American Type Culture
Collection. The cell line was chronically infected with
HIVIIIB. The cells were maintained in complete RPMI 1640
medium (ThermoFisher Scientific, Burlington, Canada)
supplemented with 1% L-glutamine, 20% fetal calf serum,
1 mM sodium pyruvate and 100 units/ml of penicillin and
streptomycin (Thermo Fisher Scientific, Canada).
Stable Tat and Tat deletion mutant-expressing cell lines
The plasmid construction, their transfection and the
subsequent selection of Jurkat E6.1 T cells stably express-
ing wildtype Tat with and without GFP as well as the Tat
deletion mutants fused to GFP was previously described
in detail [21, 40]. The impact of wildtype Tat and each of
the Tat deletion mutants on cell viability in the presence
and absence of SMX-HA was also described previously
[21]. Briefly, the Tat gene was PCR-amplified from the
plasmid pSVTat that encodes the full-length Tat gene and
was a kind gift from Dr. K.T. Jeang of the Molecular
Virology Section, NIAID, NIH. The full-length Tat gene
(Tat101), and Tat deletion mutants expressing just the first
exon (Tat72) or the full-length Tat gene without the PTD/
NLS (TatΔ) were cloned into the plasmid pEGFP-N1
(Clontech Inc., Mountain View, CA, USA), resulting in
the genes for Tat101, Tat101GFP, Tat72GFP and TatΔGFP
fusion proteins, respectively. These genes were subcloned
into pBIG2i as previously described [40]. The result was
pBIG Tat101, pBIG Tat101GFP, pBIG Tat72GFP, pBIG
TatΔGFP and pBIG GFP as a control.
The pBIG Tat constructs or pBIG GFP were trans-
fected into Jurkat-E6.1 T cells by nucleofection (Lonza,
Walkersville, MD, USA) according to the manufac-
turer’s instructions and stable cell lines were generated
as previously described [40]. The expression of both
GFP and the TatGFP fusion proteins was induced by
incubating the transfected cells with 0-1000 ng/ml
doxycycline (Dox; Sigma, Canada). Dose response and
time course of Dox induction were evaluated and char-
acterized using flow cytometry or real-time PCR while
the expression of the TatGFP constructs were con-
firmed via western blots [21].
SMX-HA
SMX-HA was synthesized by Katarina Sapeta in the la-
boratory of Dr. Michael A. Kerr at the Department of
Chemistry (University of Western Ontario, London, ON,
Canada). Sample purity was assessed using 1H NMR and
was > 96%.
Sample preparation for slot blots and redox 2D gel
electrophoresis Jurkat pBIG cells (cultured under nor-
moxic conditions) expressing wildtype or mutant forms
of Tat fused to GFP (2.5-3 × 106 cells) were induced
with 0, 200, 400 or 1000 ng/ml of Dox for 40 h
(viability > 95%) at which point the cells were washed
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twice with PBS by centrifugation at 400 x g for 5 min.
The cells were suspended in HEPES buffer and seeded
at a concentration of 0.3 × 106 cells/ml. The cells were
treated with 200 μM SMX-HA (a pharmacologically
relevant concentration [41, 42]) or the vehicle (DMSO)
(Millipore Sigma, Oakville, ON, Canada) at a final con-
centration of 0.5% then incubated at 37 °C for 2 h. The
cells were subsequently collected and lysed in RIPA
buffer containing 50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1% Triton x-100, 1% sodium deoxycholate, 0.1%
SDS, 1 mM EDTA (pH 8.0), complete mini protease
inhibitor cocktail (Roche) and 40 mM iodoacetamide
([IA]; Millipore Sigma, Oakville, ON, Canada). Protein
isolation was previously described [40] and the protein
concentrations were determined using the DC Protein
Assay (BioRad, Mississauga, ON, Canada) with bovine
serum albumin (BSA) as the standard.
Slot blot analysis Cells from the different cell lines were
incubated with Dox for 40 h then incubated with varying
concentrations of SMX-HA for 2 h under normoxic con-
ditions. The cells were then collected and protein iso-
lated as described above. Protein (1 μg) was resuspended
in cold PBS and applied to slots on the slot blot microfil-
tration device (Bio-Dot SF Apparatus, Bio-Rad) accord-
ing to the manufacturer’s instructions. Briefly, after
assembly of the Bio-Dot SF Apparatus with the pre-wet
nitrocellulose membrane, the appropriate wells were
filled with sample solution. The flow valve was then
adjusted to allow the entire sample to filter through the
membrane by gentle vacuum and each well was washed
with TBS (Tris-buffer saline, 50 mM Tris pH 7.6,
150 mM NaCl), again by pulling the wash liquid through
by filtration. After the wells were completely drained,
the membrane was removed. The membranes were sub-
sequently blocked in TBS-T (TBS with 0.1% Tween 20)
containing 5% dry milk for 1 h at room temperature
with gentle shaking, and then probed overnight at 4 °C
with an anti-SMX-HA rabbit polyclonal antibody [43] at
a dilution of 1:30000 in TBS-T. This was followed by
washing the membrane thrice for 10 min each time with
TBS-T. The secondary antibody was an HRP-conjugated
goat anti-rabbit antibody (Jackson ImmunoResearch
Laboratories) diluted to 1:35000 in TBS-T. The blots
were then treated with a chemiluminescent agent (Thermo
Scientific Pierce ECL Western Blotting Substrate) and
visualized by a Fluorchem Imager (Alpha Innotech/ Cell
Biosciences). The blots were then stripped and probed
with an anti-GAPDH monoclonal antibody (Sigma) at 1:
5000 followed by a donkey anti-mouse conjugated to HRP
(Jackson ImmunoResearch Laboratories) at 1:10000. Band
intensity was determined by the AlphaView software (Pro-
teinSimple, Santa Clara, CA, USA).
Non-reducing/reducing two-dimensional SDS/gel
electrophoresis (R2D) The two dimensional SDS-PAGE
procedure was a modified version of that reported by
Sommer and Traut [44]. Briefly, 80μg of protein
dissolved in SDS sample buffer free of reducing agents
and the proteins were resolved on a 1.0 mm thick, 10%
polyacrylamide gel by subjecting the gel to electrophor-
esis at a constant current of 16 mA for 1 h followed by
1.5-2 h at a constant current of 24 mA. After electro-
phoresis, the lane containing the separated proteins was
excised from the gel and immersed in freshly made SDS
sample buffer containing 100 mM DTT (ThermoFisher
Scientific, Burlington, ON, Canada) for 20 min at room
temperature with gentle rocking. The gel strip was washed
three times with 1× running buffer then immersed in SDS
sample buffer containing 100 mM IA for 10 min at room
temperature with gentle rocking. After another wash with
1× running buffer, the gel strip was applied horizontally to
the top of a 1.5 mm thick 10% polyacrylamide gel of
dimensions 20 cm(W) × 23 cm(L). Electrophoresis was
carried out in the second dimension at a constant current
of 135 mA for approximately 17 h. Each treatment sample
of every cell line was subjected to the above R2D protocol
at least three different times. Each set of 2D gels was
silver-stained simultaneously according to the method of
Shevchenko et al. [45]. A spot was recorded only if it was
present in at least two of the three gels.
Mass spectrometry (MS) and protein identification
Gel spots from R2D gels were identified by mass
spectrometry (MS) in the Functional Proteomics Facility
of the Department of Biochemistry at the University of
Western Ontario. Briefly, spots were excised and in-gel
digested with sequence grade trypsin and lyophilized
with a Mass Prep Automated Digestor (Waters, Milford,
MA, USA). The lyophilized samples were dissolved in
10% acetonitrile and 0.1% trifluoroacetic acid, and then
mixed with 5 mg/ml α-cyano-4-hydroxycinnamic acid
(in 6 mM ammonium phosphate monobasic solution) at
a 1:1 ratio. The samples were spotted in duplicate and
the matrix-assisted laser-desorption/ionization (MALDI)
MS spectra were acquired using a BiosystemsR 4700
Proteomics Discovery System (Applied Biosystems, Fos-
ter City, CA, USA), a matrix-assisted laser-desorption/
ionization tandem time-of-flight mass spectrometer with
TOF/TOF optics (MALDI-TOF).
The MALDI MS spectra were analyzed with the 4000
Series Explorer software (Applied Biosystems, Foster City,
CA, USA) and processed into peptide mass fingerprints
(PMF) using the Data Explorer software (Applied Biosys-
tems, Foster City, CA, USA). Protein identification from
these PMF was generated using a GPS engine connected
to a Mascot server provided by the software manufacturer.
PMF were compared to known peptide mass sequences in
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the NCBI (National Center for Biotechnological Infor-
mation) database and samples with a PMF that has a
high protein score (above 90%) were predicted to iden-
tify a specific protein.
Quantitative analysis, R2D gels To determine the
relative amount of the protein spots an area of interest
was created around the spot and the corresponding pixel
intensity values in that area were obtained. These values
were corrected for background. The value obtained for
the control, uninfected Jurkat E6.1 cells was set as 100%
and the value for the same spot in the other cell lines
calculated as a percent of this value. To determine the
molecular weights of the unknown protein spots, the
values and positions on the image of known molecular
weight markers were used as reference points. The ana-
lyses were both carried out using the AlphaView software.
Western blot analysis of peroxiredoxin 1 Jurkat pBIG
TatGFP cells (cultured under normoxic conditions) were
induced with 0, 200, 400 or 1000 ng/ml of Dox for 40 h,
washed twice with PBS, resuspended in HEPES buffer and
seeded at a concentration of 0.3 × 106 cells/ml. The cells
were then treated with 100 μM SMX-HA or the vehicle
(0.5% DMSO, v/v) (Sigma-Aldrich, Canada) and incubated
at 37 °C for 2 h. This was followed by another 2 h incuba-
tion in complete RPMI at 37 °C. The cells were subse-
quently harvested, washed in PBS and lysed in RIPA
buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
1 mM EDTA (pH 8.0) and complete mini protease inhibi-
tor cocktail (Roche, Mississauga, ON, Canada). Protein
was isolated [40] and the concentration determined using
the DC Protein Assay (BioRad, Mississauga, ON, Canada)
with bovine serum albumin (BSA) as the standard. Protein
(25 μg) was dissolved in sample loading buffer free of
reducing agents and resolved on 15% SDS-PAGE then
transferred onto PDVF membranes. Immunoblot analysis
was performed using a mouse monoclonal antibody to
peroxiredoxin 1 (Prx1) (1:5000, AbFrontier, Cedarlane
Laboratories Limited, Burlington, ON, Canada) and a
secondary antibody conjugated to horseradish peroxidase
(1:20000, Jackson ImmunoResearch, West Grove, PA).
Immunoreactivity was visualized with enhanced chemilu-
minescence (ThermoFisher Scientific, Burlington, ON,
Canada) and the Odyssey Fc Imaging System (LI-COR
Biosciences, Lincoln, NE, USA). Band densitometry was
quantified using Image Studio Lite (LI-COR Biosciences,
Lincoln, NE, USA).
Statistics
Slot blot data were analyzed in GB-Stat (Dynamic
Microsystems, Inc., Silver Spring, MD USA). Means and
standard errors (SE) were used to report continuous
variables. A two-way ANOVA with Tukey’s post hoc
procedure was used to compare mean differences be-
tween groups for different concentration levels of each
cell line. In Table 4, a two-way ANOVA with Bonferroni
post-tests was used to compare the mean differences for
Prx1 between the cell lines for each treatment.
Results
Quantification of SMX-HA-induced haptenation in
tat-expressing Jurkat T cells
To determine if expression of the HIV-1 protein Tat in
Jurkat T cells affects SMX-HA-induced haptenation,
western and slot blot experiments were conducted. Tat
cell lines were either untreated or treated with a concen-
tration of Dox that induced expression of Tat RNA simi-
lar to that observed in HIV-infected Jurkat T cells [40].
Following a 2 h exposure to increasing concentrations of
SMX-HA (0, 50, 100 and 200 μM), protein isolated from
each Tat-Jurkat cell line was subjected to western blot-
ting with an anti-SMX-HA antibody to visualize the hap-
tenation pattern. A representative example is shown
(Fig. 1a) that illustrates the qualitative differences in pro-
tein haptenation banding patterns between the different
cell lines and concentrations of SMX-HA employed
(bracket, Fig. 1b). To determine if there were quantita-
tive differences in total protein SMX-HA haptenation
between cell lines expressing wildtype or mutant Tat
constructs, slot blots were performed (representative
blot, Fig. 1b) and the hapten protein/GAPDH ratios de-
termined (representative data presented in Fig. 1c-e). Ac-
cordingly, ratios increased at least 2.5- to 3-fold when
the parental Jurkat E6.1, GFP-expressing Jurkat E6.1 and
each of the Tat-expressing Jurkat E6.1 cell lines were
treated with 50 μM SMX-HA. Moreover, these ratios
tended to increase when the SMX-HA concentration
was increased to 100 or 200 μM (representative data
shown in Fig. 1c and d). Importantly, there was no evi-
dence that the induction of the Tat constructs resulted
in significant qualitative and quantitative differences in
total SMX-HA-mediated haptenation at any tested
SMX-HA concentration (representative data shown in
Fig. 1e).
Detection of ROS-sensitive thiol proteins
Due to the many SMX-HA haptenated proteins revealed
by western blot analysis (Fig. 1), we next focused on docu-
menting oxidative changes (i.e. enhanced formation of
PSSP) arising from the treatment with the electrophilic
oxidative stressor, SMX-HA and the presence of the HIV-1
Tat protein or its deletion mutants. To explore this, a
R2D system was employed as it provides a direct means
to identify proteins that are redox regulated via oxida-
tion of reactive protein cysteine thiols through forma-
tion of protein-protein homomeric disulphides (PSSP)
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and heteromeric disulphides (PSSP’) [33]. Cell lysates
from 2.5-3 × 106 cells were analyzed by R2D. Proteins
containing reduced protein thiol (P-SH) residues prior
to first dimension gel application resolve on the
diagonal line (Fig. 2a) by molecular weight subsequent
to the gel runs in the second dimension, as
dithiothreitol (DTT) does not reduce these proteins
further. In contrast, protein-protein mixed disulphides,
following the first electrophoresis run, are reduced by
treatment with DTT in the first dimension gel matrix
so that the protein thiols formed upon reduction of
intermolecular disulphide bonds are resolved below the
diagonal line (Fig. 2a, spots 2–5). This is due to the dis-
sociation of protein dimeric disulphides and the attend-
ant decrease in molecular mass after reduction revealed
in the second dimension. However, proteins with intra-
molecular disulphide bonds after reduction with DTT
have an apparent increase in molecular mass and run
above the diagonal line after second dimension elec-
trophoresis. R2D gel electrophoresis does not resolve
S-glutathionylated proteins because of the small mo-
lecular weight change resulting from the addition of
GSH to the protein, and the removal of GSH during
DTT reduction. Each treatment condition was ana-
lyzed on the R2D gels in at least three independent
experiments and a spot was recorded only if it was
present in at least two of the three gels. Table 1 cata-
logues the protein spots resolved on the R2D gels.
HIV infection but not Tat expression alone increases
oxidation of protein thiols
Analysis of the different conditions indicated that overall
the pattern of protein spots was similar with most of the
spots resolving between 55 and 97 kDa. Representative
2D gels of protein samples are presented for different
control cell lines (Fig. 2), including the untransfected
parent cell line Jurkat E6.1 incubated with or without
1000 ng/ml Dox (Fig. 2a and d), HIV infected Jurkat T
cells (Fig. 2b) and the stably transfected Jurkat T cell line
expressing only EGFP (Fig. 2c). Observable differences
were present in both the protein abundance of spot no.
1 and the number of individually resolved protein spots
(e.g., Fig. 2a vs 2b). Of the control samples, the Jurkat-
HIV R2D protein gels revealed the greatest number of
PSSP and PSSP’-derived spots (Fig. 2b and Table 1), indi-
cative of increased oxidative stress and/or the presence
Fig. 1 Representative western blot and slot blot data showing SMX-HA-induced haptenation. a Western blot of cells treated with 0 (lanes 1–3), 100 μM
(lanes 4–6) and 200 μM (lanes 7–9) SMX-HA for 2 h and resolved on 12% SDS-PAGE. Lanes 1, 4, 7: Jurkat E6.1; lanes 2, 5, 8: Tat101GFP; lanes 3, 6, 9:
Tat72GFP. b Total protein from cells treated with various concentrations of SMX-HA and applied onto a membrane via a slot blot apparatus. Both mem-
branes were blotted with anti-SMX-HA antibody. The band intensities were measured digitally and the ratio of SMX-HA haptenation to GAPDH
content in the corresponding sample was calculated. (C and D) The SMX-HA/GAPDH ratio increases with increasing concentration of SMX-HA
for GFP (c) and wildtype Tat101 (d) expressing Jurkat E6.1 cells. Significance was defined as follows: a, c, e P < 0.05 vs. 0, 400, 1000 ng Dox ml−
1 at 0 μM SMX-HA, respectively. b, d, f P < 0.05 vs. 0, 400, 1000 ng Dox ml− 1 at 50 μM SMX-HA, respectively. g P < 0.05 vs. 200 ng Dox ml− 1 at
100 μM SMX-HA. e Expression of wildtype Tat101 and Tat mutants does not result in significantly different SMX-HA/GAPDH ratios compared
to untransfected Jurkat E6.1 and GFP expressing cells. Data are expressed as mean of three independent experiments
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of novel redox-related proteins in HIV-infected cells.
The majority of the protein disulphides formed have
intermolecular bonds as they resolved below the diag-
onal line on R2D. The Jurkat E6.1 cell line (Fig. 1a) had
seven identical protein spots to Jurkat-HIV cells while
Jurkat E6.1 cells incubated with 1000 ng/ml Dox only
showed five proteins common with Jurkat-HIV cells (Fig.
2d). Jurkat cells transfected with EGFP had the fewest
spots (Fig. 2c). Data from the un-induced (0 ng/ml Dox)
samples from the different Tat transfected cell lines are
summarized in Table 1 with representative gels shown in
Additional file 1: Figure S1. They revealed very similar
patterns and numbers of spots as observed for the Jurkat
E6.1 and GFP transfected control cell lines.
Next, we examined the gel pattern of the different cell
lines treated with either 400 or 1000 ng/ml Dox that
induce Tat or TatGFP mRNA expression to equivalent
or elevated levels, respectively, present in HIV-infected
Jurkat cells [21]. Generally, this resulted in the appear-
ance of the same protein spots and occasionally in the
loss of a protein spot previously seen in R2D gels of the
0 ng/ml Dox samples (Fig. 2, Table 1 and Additional file 2
Figure S2). Over expression of Tat induced with 1000 ng/
ml Dox in the transfected cell lines (Fig. 3c-f) did not
drastically change the number or identity of proteins that
resolved away from the diagonal compared to 0 ng/ml
Dox (Additional file 1: Figure S1) or when induced with
400 ng/ml Dox (Additional file 2 Figure S2). All the re-
solved proteins were equivalent to those seen from the
parental cell line or the HIV infected cell line (Table 1).
The exception was the TatΔGFP cell line where two novel
proteins with approximate molecular weights of 44 kDa
(Fig. 3f, spots 10 and 11) were found above the diagonal
line. For this cell line, TatΔGFP induction at 1000 ng/ml
Dox resulted in protein spots 10 and 11 tending to appear
with greater intensity than seen following induction at
400 ng/ml Dox (Fig. 3f vs Additional file 2: Figure S2F),
the concentration that generates Tat mRNA equivalent
to that in HIV-infected cells [21]. Thus, in the absence
of SMX-HA, wild type Tat and the Tat deletion
Fig. 2 R2D SDS-PAGE of thiol proteins from control cell lines. Samples from (a) Jurkat E6.1, (b) Jurkat-HIV, (c) GFP and (d) Jurkat E6.1 + 1000 ng/ml Dox.
The sample from panel D was incubated with 1000 ng/ml doxycycline for 40 h. Cells from each cell line were then treated with 0.5% DMSO for 2 h,
collected and protein was isolated. Protein lysate (85 μg) was loaded onto the first dimension gel and run for 3 h followed by an overnight run of the
second dimension gel. On the left side of the diagonal on each gel are molecular weight protein standards that are enumerated to the left of panels a
and c. The gels shown in panels a and b are duplicated and used as a reference in panels a and b of Fig. 3 and Additional file 1: Figure S1 and Additional
file 2: Figure S2
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mutants do not appear to have a significant impact on
the disulphide proteome.
The combination of high tat expression and SMX-HA
treatment produced the highest number of oxidized
protein-protein mixed disulphides (PSSP and PSSP’)
Cell lines treated with 200 μM SMX-HA showed a 2-
to 3-fold increase in the number of proteins resolved
below the diagonal line in addition to the oxidized pro-
tein spots observed in the absence of SMX-HA (Fig. 4,
spots 1–18, Table 1). The proteins that resulted from
the oxidative stress uniquely resulting from the addition
of electrophilic SMX-HA are lettered a-s (Fig. 4a-d;
Additional file 3: Figure S3A-F, Table 1). These hapte-
nated proteins could not be identified by mass spec-
trometry due to limiting amounts.
Treatment of the parental cell line Jurkat E6.1 with
SMX-HA did not affect the resolution of any of the
numbered proteins, but added new oxidized proteins
to the profile (Table 1 and Fig. 4a). SMX-HA-treatment
of Jurkat E6.1 T cells induced with 1000 ng/ml Dox
(Fig. 4d) tended to reduce the abundance of the protein
in spots 3 and 4 indicating lower amounts of these pro-
teins were oxidized (i.e. occur as PSSP). The treatment
of the HIV-infected Jurkat cell line with SMX-HA
caused the loss of some proteins, but also dramatically
increased the number of protein spots including two
unique protein spots k and l (Table 1 and Fig. 4b). R2D
gel electrophoresis of samples from the cell line ex-
pressing EGFP (the negative control) resulted in the
resolution of proteins common to the parental cell line,
but none of the novel lettered proteins (Table 1 and
Fig. 4c).
Treatment of the uninduced cells (0 ng/ml Dox) with
SMX-HA resulted in the Tat72GFP and TatΔGFP cell
lines displaying the most protein spots from the Tat--
transfected cell lines (Table 1 and Additional file 3: Fig-
ure S3E and F). The majority of these proteins contain
intermolecular disulphide bonds, running below the di-
agonal line of unresolved proteins. Maximal induction of
Tat expression with 1000 ng/ml Dox generated the most
protein spots, reflecting enhanced oxidative stress. In
Table 1 Summary of protein-protein mixed disulphide-derived spots found in the R2D gels of lysates from the cell lines used in this
investigation
Black squares indicate the presence of the corresponding protein spot in that cell line and red squares represent the presence of the corresponding protein spot in that
cell line only after treatment with 200 μM SMX-HA. J-E6.1 + Dox: Jurkat E6.1 cells incubated with 1000 ng/ml doxycycline (Dox). Jurkat HIV: Jurkat E6.1 cells infected with
HIV. *Concentrations of Dox selected to induce a level of TatGFP mRNA equivalent to that seen in HIV-infected Jurkat T cells. For the Tat101GFP and Tat72GFP cell lines
200 ng/ml Dox was used, whereas 400 ng/ml Dox was used for all other cell lines
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addition to the resolution of previously documented pro-
teins, the TatΔGFP cell line also produced three unique
proteins o, p and q (Table 1 and Fig. 5f ).
Peroxiredoxins as a measure of cellular oxidative stress in
Jurkat T cells
The R2D gel system revealed a number of proteins
with intermolecular disulphide bonds (below the line),
but most notably there were intense spots detected
just below 30 kDa (elliptically circled in white) and
labelled as spot 1 in all R2D Figure panels. After iso-
lation from the R2D gel, both the top and bottom
proteins were in-gel digested with trypsin and identi-
fied by MALDI-TOF mass spectrometry as Prx1 and
Prx2, respectively (Tables 2 and 3).
The Prx proteins in the parental Jurkat E6.1 cell line
consistently showed the highest abundance relative to
those in the other control and Tat-expressing cell lines.
The densitometric value of these Prx proteins served as
a benchmark (100%) against which the Prx proteins
from the other cell lines were compared. The untreated
samples (0μM SMX-HA) from the Tat-expressing cell
lines were found to be reduced to 31–42% in relation to
the intensity of protein Prx1 (spot no. 1; Table 4 and
Additional file 1: Figure S1). The relative abundance of
Prx in the untreated Jurkat HIV samples (0μM SMX-
HA) was also reduced to 44% in relation to Prx1 (spot
no. 1) of untreated Jurkat E6.1 cells (Table 4). The R2D
gels of the different cell lines induced with 1000 ng/ml
Dox and treated with 200μM SMX-HA revealed a
Fig. 3 R2D SDS-PAGE of thiol proteins formed by reduction of cellular protein-protein mixed disulphides. Samples from (a) Jurkat E6.1, (b) Jurkat-HIV,
(c) Tat101, (d) Tat101GFP, (e) Tat72GFP and (f) TatΔGFP, with panels c-f induced for 40 h with 1000 ng/ml Dox prior to DMSO treatment. The R2D gels
in panels a and b are replicas of those seen in Fig. 2a and b respectively. Cells from each of the various lines were treated with 0.05% DMSO for 2 h,
collected and the protein was isolated. Protein lysate (85 μg) was loaded onto the first dimension gel and run for 3 h followed by an overnight run of
the second dimension gel. On the left side of the diagonal on each gel are molecular weight protein standards that are enumerated to the left of
panels a, c and e
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further decrease in the relative abundance of Prx in all
cell lines (Table 4 and spot no.1, Figs. 4 and 5; Add-
itional file 3 Figure S3 and Additional file 4 Figure S4).
In this instance, the Prx abundance for the Jurkat HIV
cell line decreased to 33% followed by the Tat101 cell
line, which decreased to 23% in relation to untreated
Jurkat E6.1 cells (0 Dox, 0 SMX-HA). The Tat72GFP
and TatΔGFP cells saw Prx abundance decrease to 10%
in relation to Prx1 (spot no. 1) in untreated Jurkat E6.1
cells, suggesting they were most affected by SMX-HA-
induced oxidative stress (Table 4 and Additional file 3:
Figure S3). Upon Tat induction (400 ng/ml Dox), the
Tat101GFP cell line showed an increased intensity
for Prx. By comparison in the presence of SMX-HA,
the abundance for Prx in the Tat101, Tat72GFP and
TatΔGFP transfected cell lines tended to be de-
creased further (Table 4).
Peroxiredoxin 1 redox changes
Peroxiredoxins (Prx) are ubiquitous and highly expressed
peroxidases that use reversibly oxidized cysteine residues
to reduce peroxides (H2O2) [46]. Given the abundance of
Prx1 seen in the R2D gels as well as the fact that Prx1
serves as a sensitive marker of oxidation in cells [46], we
used non-reducing SDS-PAGE and an anti-Prx1 antibody
to examine the oxidation state of Prx1 after expression of
the different Tat constructs and SMX-HA treatment. This
method relies on the fact that cell lysis in the absence of
an alkylating agent will result in the oxidation of reduced
Prx leading to the formation of disulfide-linked dimers of
~ 44 kDa, while hyperoxidized Prx1 is unable to dimerize
and therefore will remain as a monomer at ~ 22 kDa [47].
The ratio of monomer to dimer serves as a specific marker
of oxidative stress [48, 49].
The oxidation of Prx1 was examined in the four Tat-ex-
pressing cell lines. Cells were induced with Dox for 48 h
prior to incubation with vehicle (DMSO) or 100 μM
SMX-HA. Lower concentrations of SMX-HA (100 μM)
were used to maintain cell viability, particularly in cells
expressing TatΔGFP as they are highly sensitive to SMX-
HA [21]. Differential Tat expression in the absence of
SMX-HA did not result in significant changes of the Prx1
monomer/dimer ratio in any of the cell lines (Fig. 6).
However, induction of Tat101GFP expression in the pres-
ence of 100 μM SMX-HA decreased the monomer/dimer
ratio while the ratio for the TatΔGFP cell line increased
under these treatment conditions. The maximal level of
Fig. 4 R2D SDS-PAGE of thiol proteins from control cell lines treated with SMX-HA. Samples from (a) Jurkat E6.1, (b) Jurkat-HIV, (c) GFP and (d) Jurkat E6.1
+ 1000 ng/ml dox. The sample are from panel D was incubated for 40 h with 1000 ng/ml Dox prior to drug treatment. Cells from each of the various lines
were then treated with 200 μM SMX-HA for 2 h, collected and the protein was isolated. Protein lysate (85 μg) was loaded onto the first dimension gel and
run for 3 h followed by an overnight run of the second dimension gel. The gels shown in panels A and B are duplicated and shown as a reference in
panels A and B of Fig. 5 and Additional file 1: Figure S1 and Additional file 2: Figure S2. On the left side of the diagonal on each gel are molecular weight
protein standards that are enumerated the left of panels a and c
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TatΔGFP expression (1000 ng/ml Dox) combined with
SMX-HA treatment led to a significant increase of the
monomer/dimer ratio compared to the other Tat-
expressing cell lines (Fig. 6), suggesting the TatΔGFP cell
line is more susceptible to the hyperoxidation of Prx1
under those conditions.
Discussion
The Hapten Hypothesis is one of the most widely
accepted mechanisms for the development of hypersen-
sitivity ADRs. This hypothesis contends that the initial
step(s) in the pathogenesis of hypersensitivity ADRs
involve(s) the metabolic bioactivation of the drug to a
hapten with inherent immunogenicity that then elicits
an undesired immune response. In the case of SMX, its
reactive oxidative metabolite (SMX-HA) can be further
oxidized to SMX-NO, which, subsequent to covalent
binding to protein(s), is postulated to be a hapten that
elicits an immune response [43, 50, 51]. Our results
demonstrate that the degree to which haptenation
occurs is dependent on the concentration of SMX-HA
but independent of HIV-I infection or whether wildtype
or mutant forms of Tat are expressed in the Jurkat cell
lines. Hence, we focused on the ability of SMX-HA/
SMX-NO to induce intracellular oxidative stress by
generating ROS [21, 52] and ROS-dependent GSH de-
pletion rather than the immunological consequences of
haptenation. Given the high incidence (up to 50%) of
Fig. 5 R2D SDS-PAGE of thiol proteins from cell lines treated with SMX-HA. Samples from (a) Jurkat E6.1, (b) Jurkat-HIV, (c) Tat101, (d) Tat101GFP,
(e) Tat72GFP and (f) TatΔGFP, the last four panels showing samples induced for 40 h with 1000 ng/ml doxycycline prior to drug treatment. The
R2D gels in panels a and b are replicas of those in Fig. 4a and b, respectively. Cells from each of the various lines were then treated with 200 μM
SMX-HA for 2 h, collected and the protein was isolated. Protein lysate (85 μg) was loaded onto the first dimension gel and run for 3 h followed
by an overnight run of the second dimension gel. On the left side of the diagonal on each gel are molecular weight protein standards that are
enumerated to the left of panels a, c and e
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hypersensitivity ADRs in the HIV population [41] as
well as Tat’s ability to down-regulate three regulators
of ROS (manganese-SOD, selenoglutathione peroxid-
ase and glutathione synthase), HIV-infected cells as
well as cells subjected to extracellular Tat would be
more sensitive to the effects of ROS and GSH deple-
tion on exposure to SMX-HA [11, 53].
For this study we exposed wildtype, HIV-infected and
Tat mutant transfected Jurkat cell lines to concentrations
of SMX-HA that ranged from 0 to 200 μM. Patients
treated with SMX (0.5–2 g/dose) or its derivatives have
plasma concentrations that range widely from 40 to
600 μM [54–56]. All patients treated with SMX also
appear to contain SMX-HA [57]. Cells, including circu-
lating peripheral blood mononuclear cells that take up
SMX-HA, further metabolize it to the more reactive
metabolite, SMX-NO. This nitroxide metabolite is likely
the chemical species that haptenates proteins [58].
Exposure to HIV or to the Tat constructs increases
oxidative stress which, in turn, results in reduced intra-
cellular GSH [9], promoting the conversion of SMX-HA
to SMX-NO. In vivo, about 5% of the input SMX is con-
verted to reactive metabolites SMX-HA and SMX-NO
[24, 25] but how this relates to SMX-HA and SMX-NO
concentrations in the blood and in secondary lymphoid
tissues has not been measured. Using estimates of total
plasma-derived water content (~ 3 L) [59, 60] and that
up to 5% of a 0.5–2 g dose of SMX undergoes [24, 25]
conversion, the combined concentration of SMX-HA/
SMX-NO might reach the 30-120 μM range under ideal
conditions.
Human leukocytes exposed in vitro to various concentra-
tions of SMX-HA (1-800 μM) demonstrate reductions in
leukocyte proliferation and viability as well as functional
alterations [42, 59, 61–63]. In addition, leukocytes exposed
to similar SMX-HA concentrations were sufficiently hapte-
nated on the cell surface to elicit proliferative responses
from Tcells taken from humans exhibiting SMX hypersen-
sitivity reactions [64]. In vitro, SMX fails to elicit such
responses. This study and our previous studies examining
the effects of HIV infection and Tat expression on SMX-
mediated ADRs employed concentrations of SMX-HA
(50-200 μM) in the lower end of the concentration range
experimentally utilized in the literature. We selected this
range in order to minimize the effect of SMX-HA on cell
viability and because the selected range overlaps with our
estimates and those of other estimates of what likely
represents pharmacologically relevant concentrations
of SMX-HA [57, 59, 65]. In AIDS patients, changes in
drug metabolism that could contribute to elevated
levels of the toxic metabolites SMX-HA and SMX-NO
due to reductions in GSH content may place them at
an elevated risk for SMX adverse drug reactions due to
the higher doses of SMX employed to treat opportun-
istic infections [59, 66, 67].
The main targets of small molecule electrophiles such
as SMX-HA are amino acid side chains with nucleo-
philic properties such as the ionized cysteine sulfhydryl
group, the N-terminal amino group and the histidine
imidazole group [68]. As post-translational modification
of activated cysteine residues of proteins is critical in
redox regulation, we evaluated the effect of SMX-HA/
SMX-NO on the oxidation of protein cysteine thiols
using R2D gel electrophoresis to test for increased oxi-
dation of redox-regulated proteins to PSSP and PSSP’
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to identify the disulphide bonded protein separated by R2D gels. The protein was determined to be peroxiredoxin 1 (Homo sapiens), a member of the
peroxiredoxin family of antioxidant enzymes
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protein-protein disulphides, a critical component of the
disulfide proteome.
The GFP cell line had the fewest protein-protein
disulphide-derived spots. The TatΔGFP cell line consist-
ently displayed more protein spots in the R2D gels than
the other Tat-expressing cell lines. This likely relates to
the cellular distribution of the Tat constructs. With the
exception of the aforementioned TatΔGFP construct,
which lacks an NLS, the other Tat proteins are predom-
inantly nuclear [21]. While TatΔGFP also has a nuclear
presence, the loss of the NLS renders it cytoplasmic at
high levels where, as we have shown previously [21], it
has additional effects not seen in the other Tat-
expressing cell lines. Indeed, the TatΔGFP construct
significantly decreases Jurkat T cell viability in the pres-
ence of SMX-HA [21].
The use of the soluble fraction of the protein samples
in the R2D gels provides further enrichment for cyto-
plasmic localized protein disulphides and thus Prx1
(spot 1), the main cytoplasmic form of Prx1 in Jurkat
cells and the predominant spot on the R2D gels in con-
trol cells. Spot 1 was confirmed as Prx1 by mass spec-
trometry, which is in agreement with the identification
made by others [33, 36]. Peroxiredoxins (Prx) are a fam-
ily of antioxidant proteins approximately 21-30 kDa in
size that use specialized cysteines to decompose perox-
ides. The mammalian Prx family has six members (Prx1
to Prx6) differentially expressed in different subcellular
Table 4 Spot intensities of the peroxiredoxin proteins
SMX-HA 0μM 200μM
Dox (ng/ml) 0 400 1000 0 400 1000
Jurkat E6.1 100 ± 1 n/d n/d 33 ± 1.4 n/d 37 ± 2.0
Jurkat HIV 44 ± 2.2*** n/d n/d 33 ± 0.6 n/d n/d
Tat101 31 ± 1.1***† 46 ± 1.4*** 35 ± 0.1*** 31 ± 4.4 8.5 ± 0.3***††† 23 ± 0.5***
Tat101GFP 34 ± 1.4*** 30 ± 0.6***† 32 ± 0.8*** 12 ± 2.4***††† 41 ± 1.4 18 ± 2.5***†
Tat72GFP 44 ± 4.1*** 41 ± 0.3*** 39 ± 1.0*** 7.8 ± 0.1***††† 6.7 ± 1.2***††† 7.8 ± 0.7***†††
TatΔGFP 33 ± 4.0*** 43 ± 0.6*** 35 ± 0.6*** 13 ± 1.1**† 10 ± 0.1***† 9.5 ± 0.4***†
Values for each of the R2D gels were calculated as a percentage of the spot intensity for protein 1 of the Jurkat E6.1 sample. n/d: not done. ***p < 0.001, **p < 0.01
vs. Jurkat E6.1 and †††p < 0.001, †p < 0.05 vs. Jurkat HIV
Fig. 6 The effect of Tat expression and SMX-HA-mediated oxidative stress on Prx1 oxidation in Jurkat T cells. Cells from the various cell lines were induced
with 0, 400 or 1000 ng/ml Dox for 48 h, treated with 0. 5% DMSO or 100μM SMX-HA for 2 h followed by another 2 h incubation in media. The cells were
then collected, cell lysates prepared and 25μg protein were dissolved in non-reducing loading buffer. The protein samples were run on 15%
SDS-PAGE and transferred to membranes that were then probed with antibodies to Prx1. a A representative immunoblot showing oxidized
dimers (labelled D on blots) and hyperoxidized monomers (labelled M on blots). b Quantification of the Prx1 monomer:dimer ratio in the
Tat-expressing cell lines, presented as means ± S.E
Adeyanju et al. Virology Journal  (2018) 15:82 Page 13 of 17
compartments with Prx1 as the major cytoplasmic form
in Jurkat T cells [69]. Prx1 is a 2-Cys Prx that exists as
non-covalently-linked homodimers and carries out per-
oxide detoxication in three main steps: peroxidation,
resolution and recycling [70, 71]. The Prx catalytic cycle
begins with H2O2 oxidizing the peroxidatic (reactive)
cysteine of a Prx molecule to form sulfenic acid (Prx-
SOH), which can condense with the resolving cysteine
of a neighbouring Prx molecule to form an intermolecu-
lar disulfide bond [48]. The resulting Prx dimer can be
reduced by the thioredoxin system in eukaryotes [46,
48]. However, under high H2O2 concentrations, an alter-
native to disulfide formation can occur, leading to the
hyperoxidation of Prx to the sulfinylated (Prx-SO2H)
and sulfonylated (Prx-SO3H) forms [48]. Although these
hyperoxidized forms can be slowly reduced by sulfire-
doxin in an ATP-dependent reaction in vivo, under our
assay conditions they remain enzymatically inactivated
resulting in the inhibition of peroxidase function [48,
72]. It has been proposed that inactivation of Prx may
be crucial for H2O2 to accumulate and react with cyste-
ines in proteins that are normally slower to react than
Prx, thereby enabling the redox reactions required to
relay downstream signalling [73].
With excess ROS, Prxs becomes hyperoxidized during
the catalytic cycle, leading to loss of Prx thiols and
enzyme inactivation [74–77]. The decrease of the Prx1
protein disulphide (spot 1) seen in HIV-infected cells
confirms that these cells are under more oxidative stress
than the parental Jurkat E6.1 cells, consistent with HIV
infection [31, 78, 79]. The further decrease in Prx1 pro-
tein levels in the Tat-expressing cells compared to the
HIV-infected cells suggests there was inactivation of the
enzyme due to further, uncompensated, oxidation and
that the expression of Tat or its deletion mutants re-
sulted in additional oxidative stress (vs HIV infection)
within the Jurkat T cells. This would be enhanced in the
presence of SMX-NO which reacts rapidly with GSH to
form a labile semimercaptal derivative, consuming intra-
cellular GSH [50]. This unstable SMX-semimercaptal is
isomerized to a more stable sulfinamide with the release
of SMX-HA. The sulfur atom of the sulfinamide is de-
rived from GSH and the released SMX-HA can deplete
another molecule of GSH upon re-oxidation to SMX-
NO (i.e. a futile metabolic cycle).
Exposure of the different Tat-expressing cell lines to
pharmacologically-relevant concentrations of SMX-HA
also lead to additional hyper-oxidation and inactivation
of the Prx enzymes in all the Tat-expressing cell lines
studied. For the cell lines expressing Tat101, Tat72GFP
and TatΔGFP, the decrease in the abundance of the Prx
disulphide spot after treatment with SMX-HA was more
pronounced than that seen in the HIV-infected cells.
This suggests that cell lines chronically infected with
HIV may compensate for the loss of the Prx enzymes
produced by the oxidative stress of SMX-HA by mecha-
nisms yet to be defined. One probable reason for the
apparent decrease in the amount of the Prx disulphide
in the Tat-expressing cells after the treatment with
SMX-HA is that the Tat protein is able to suppress the
expression and activity of other important cellular anti-
oxidants such as GSH and Mn-SOD [11, 12].
In an effort to determine whether expression of the
different Tat constructs has any effect on the propensity
for Prx1 hyperoxidation a non-reducing SDS-PAGE
analysis of the cell lines was conducted. The ratio of
monomeric to dimeric forms of Prx1 revealed that the
expression of TatΔGFP treated with the relatively low
dose of 100μM SMX-HA made the cells more suscep-
tible to Prx1 hyperoxidation. According to the floodgate
model put forth by Wood et al. [73], this outcome was
expected as the R2D SDS-PAGE data showed that the
TatΔGFP cell line produced the greatest number of spots
amongst the Tat-expressing cell lines. The floodgate
model proposed that at low concentrations H2O2 is
reduced by Prx, but as the concentration increases, Prx
are inactivated by hyperoxidation thus allowing H2O2 to
accumulate and oxidise other target proteins [72, 73].
The hyperoxidation of Prx1 in the TatΔGFP-expressing
cell line likely resulted in the oxidation of numerous
other unique cysteine thiol target proteins to disulphides
that then appeared on the R2D gels.
All eukaryotic Prx are inherently sensitive to hyperoxi-
dation though studies have shown some are more resili-
ent to hyperoxidation than others [80]. This is based on
several factors including the rate of Prx disulphide for-
mation, but also the local environment. For instance, in
vitro, the ER-localized Prx4 has a similar sensitivity to
hyperoxidation to cytosolic Prx1, but in vivo a negligible
amount of Prx4 becomes hyperoxidized due to the low
amount of disulphide reductase in the ER, which causes
Prx4 disulphides to accumulate instead [46]. Both sce-
narios could apply in our case as the SMX-HA treat-
ment following increasing TatΔGFP expression resulted
in a decrease in dimer formation (data not shown) sug-
gesting the increased cytoplasmic presence of TatΔGFP
may affect the H2O2 buffering capacity of the cell due to
the initial availability of reduced protein thiols. Thus, in
addition to the NLS being important at the transcrip-
tional level, the Tat NLS may ensure that the infected
cell’s viability is maintained to allow viral replication to
take place by minimizing Tat’s presence in the cyto-
plasm. Further investigation will be required to identify
the unique disulphide proteins identified in cell lysates
from cells infected with HIV and expressing wildtype
type Tat and its mutants. It is possible that these unique
disulphide proteins, especially those identified in the
TatΔGFP expressing cells following SMX-HA exposure,
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play a critical role in maintaining cellular redox homeo-
stasis and cell viability.
Conclusion
The amount of overall protein haptenation by SMX-HA/
SMX-NO is independent of the presence and cellular
distribution of HIV Tat. HIV infection leads to an increase
in the number of mixed protein-protein disulphides (PSSP
or PSSP’) present. Wildtype Tat and the mutants tested, in
the absence of SMX-HA, significantly altered the disul-
phide proteome. The R2D SDS-PAGE experiments con-
firmed SMX-HA enhanced oxidative stress leading to the
increased formation of mixed protein disulphides and the
hyperoxidation of Prx1 in Jurkat T cells. In the presence of
SMX-HA, unique disulphide proteins were identified in
HIV infected and Tat mutant expressing cell lines. The
cell line expressing the TatΔGFP mutant, which accumu-
lates in the cytoplasm, showed the most sensitivity to Prx1
hyperoxidation and inactivation, leading to the oxidation
of unique target proteins that could be essential for cellu-
lar homeostasis and thus influence the complex pathogen-
esis of drug hypersensitivity. These findings indicate that
the combination of HIV Tat and SMX-HA may alter the
activity of cellular proteins required for redox homeosta-
sis. Our previous data [21, 40] showed that HIV Tat and
SMX-HA, in combination, accentuate the cytopathic
effects associated with HIV infection of T cells. Inducing
elevated levels of Tat72GFP in a dose-dependent manner
resulted in decreased viability, increased release of cyto-
chrome C and activation of caspase-3 suggesting apoptosis
as a mechanism of cell death [9, 40]. Subsequently, using
the same constructs employed in this report, we previ-
ously demonstrated reduced cell viability of cells trans-
fected with Tat deletion mutants that were substantially
present in the cytoplasm [21]. We also previously demon-
strated SMX-HA results in increased ROS production via
the C-terminal half of Tat [21]. Thus, when our earlier
data is considered in the context of the results presented
here, it enables us to propose the following model. The
combined consequences of SMX-HA and an HIV Tat al-
tered cellular redox state sets the stage for the initiation of
an ADR in which Tat accentuates the release of hapte-
nated proteins from dying cells, providing the antigens ne-
cessary for the induction of a T cell-mediated
hypersensitivity reaction.
Additional files
Additional file 1: Figure S1. R2D SDS-PAGE of thiol proteins, formed by
reduction of cellular protein-protein mixed disulphides, in lysates of (A) Jurkat
E6.1, (B) Jurkat-HIV, (C) Tat101, (D) Tat101GFP, (E) Tat72GFP and (F) TatΔGFP at
0 ng/ml Dox. The R2D gels in panels A and B are replicas of those presented
in Fig. 2. Cells from each of the various lines were treated with 0.05% DMSO
for 2 h, collected and the protein was isolated. Protein lysate (85 μg) was
loaded onto the first dimension gel and run for 3 h followed by an overnight
run of the second dimension gel. On the left side of the diagonal on each
gel are molecular weight protein standards that are enumerated to
the left of panels A, C and E. (TIF 4102 kb)
Additional file 2: Figure S2. R2D SDS-PAGE of thiol proteins, formed by
reduction of cellular protein-protein mixed disulphides, in lysates of (A) Jurkat
E6.1, (B) Jurkat-HIV, (C) Tat101, (D) Tat101GFP, (E) Tat72GFP, (F) TatΔGFP, with
panels C-F induced for 40 h with 400 ng/ml Dox (C and F) and 200 ng/
ml Dox (D and E) prior to DMSO treatment. The redox 2D gels in panels
A and B are replicas of those represented in Fig. 2. Cells from each of
the various lines were treated with 0.05% DMSO for 2 h, collected and
the protein was isolated. Protein lysate (85 μg) was loaded onto the first
dimension gel and run for 3 h followed by an overnight run of the sec-
ond dimension gel. On the left side of the
diagonal on each gel are molecular weight protein standards that are
enumerated the left of panels A, C and E . (TIF 4107 kb)
Additional file 3: Figure S3. R2D SDS-PAGE of thiol proteins formed by
reduction of cellular protein-protein mixed disulphides, in lysates of (A)
Jurkat E6.1, (B) Jurkat-HIV, (C) Tat101, (D) Tat101GFP, (E) Tat72GFP and (F)
TatΔGFP at 0 ng/ml Dox. The R2D gels in panels A and B are replicas of
those represented in Fig. 4. Cells from each of the various lines were
treated with 200 μM SMX-HA for 2 h, collected and the protein was
isolated. Protein lysate (85 μg) was loaded onto the first dimension gel
and run for 3 h followed by an overnight run of the second dimension
gel. On the left side of the diagonal on each gel are molecular weight
protein standards that are enumerated to the left of panels A, C and E.
(TIF 3759 kb)
Additional file 4: Figure S4. R2D SDS-PAGE of thiol proteins formed by
reduction of cellular protein-protein mixed disulphides, in lysates of (A)
Jurkat E6.1, (B) Jurkat-HIV, (C) Tat101, (D) Tat101GFP, (E) Tat72GFP and (F)
TatΔGFP, induced for 40 h with 400 ng/ml Dox (C and F) and 200 ng/ml
Dox (D and E) prior to drug treatment. The R2D gels in panels A and B are
replicas of those represented in Fig. 4. Cells from each of the various lines
were then treated with 200 μM SMX-HA for 2 h, collected and the protein
was isolated. Protein lysate (85 μg) was loaded onto the first dimension gel
and run for 3 h followed by an overnight run of the second dimension gel.
On the left side of the diagonal on each gel are molecular weight protein
standards that are enumerated to the left of panels A, C and E. (TIF 3762 kb)
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